Fighting Counterfeit Medicines in Europe: The Effect on Access to Medicines

  • Van Baelen M
  • Dylst P
  • Pereira C
  • et al.
N/ACitations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The implementation of the Falsified Medicines Directive, and its Delegated Regulation with detailed specifications of safety features, will provide an additional obstacle for counterfeiters. The implementation of the Directive aims to prevent falsified medicines from reaching patients, and is in the interest of public health. However, the financial burden for manufacturers to implement these additional safety features, as well as the repository system that will allow the verification of authenticity of individual packs of medicine, may threaten the availability of medicines.

Cite

CITATION STYLE

APA

Van Baelen, M., Dylst, P., Pereira, C. L., Verhaeghe, J., Nauwelaerts, K., & Lyddon, S. (2017). Fighting Counterfeit Medicines in Europe: The Effect on Access to Medicines. Medicine Access @ Point of Care, 1. https://doi.org/10.5301/maapoc.0000010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free